| Followers | 116 |
| Posts | 12965 |
| Boards Moderated | 2 |
| Alias Born | 01/29/2015 |
Monday, May 12, 2025 4:05:11 PM
The pump before the dump! Look out below. Super cave Tuesday coming.
Bearish
Recent LLY News
- FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions • PR Newswire (US) • 04/01/2026 03:30:00 PM
- Hopes of Iran War Resolution Spark Broad Rally on Wall Street • IH Market News • 03/31/2026 08:31:16 PM
- Alkermes shares jump 13% after Lilly announces sleep-disorder acquisition • IH Market News • 03/31/2026 02:55:46 PM
- Novo Nordisk introduces discounted Wegovy subscription plan in the U.S. • IH Market News • 03/31/2026 02:46:32 PM
- Centessa shares soar after Lilly announces multibillion-dollar acquisition deal • IH Market News • 03/31/2026 02:42:29 PM
- Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders • PR Newswire (US) • 03/31/2026 10:45:00 AM
- Eli Lilly strikes $2.75 billion drug discovery partnership with InSilico • IH Market News • 03/30/2026 09:33:40 AM
- Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity • PR Newswire (US) • 03/28/2026 07:15:00 PM
- Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis • PR Newswire (US) • 03/27/2026 01:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 03/26/2026 10:02:53 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/20/2026 08:23:04 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/20/2026 08:19:30 PM
- Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes • PR Newswire (US) • 03/19/2026 10:45:00 AM
- Stronger-Than-Expected Inflation Figures Could Pressure Wall Street: Dow Jones, S&P, Nasdaq, Futures • IH Market News • 03/18/2026 01:17:18 PM
- Wall Street seen lower as stronger inflation data clouds outlook before Fed decision: Dow Jones, S&P, Nasdaq, Futures • UK Market News • 03/18/2026 01:17:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 08:32:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 08:31:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 08:30:41 PM
- Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis • PR Newswire (US) • 03/16/2026 10:45:00 AM
- Lilly flags impurity in compounded versions of its weight-loss drug, warns of potential health risks • IH Market News • 03/12/2026 11:01:06 AM
- Eli Lilly plans $3 billion China investment, files for approval of new GLP-1 treatment • IH Market News • 03/11/2026 01:51:37 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/06/2026 09:35:56 PM
- Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients • PR Newswire (US) • 03/05/2026 11:00:00 AM
- Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion • PR Newswire (Canada) • 03/03/2026 02:00:00 PM
- Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion • PR Newswire (US) • 03/03/2026 02:00:00 PM
